How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Jennifer Jarrett, insider at Arcus Biosciences

Jennifer Jarrett Insider Information

Jennifer Jarrett serves as Chief Operating Officer, Director of the Company. Ms. Jarrett currently serves as Vice President, Corporate Development and Capital Markets at Uber, Inc. Ms. Jarrett served as our Chief Operating and Financial Officer from June 2018 to January 2019, and as our Chief Business Officer and Chief Financial Officer from March 2017 to June 2018. From April 2016 to September 2016, Ms. Jarrett was the Chief Financial Officer of Medivation, Inc., a biopharmaceutical company, which was acquired by Pfizer Inc. Prior to that, Ms. Jarrett spent 20 years in investment banking, most recently as Managing Director at Citigroup from July 2010 to April 2016, where she was responsible for managing their west coast life sciences investment banking practice. Before that, Ms. Jarrett was a Director and Managing Director at Credit Suisse from 2000 to 2010, and an associate at Donaldson, Lufkin & Jenrette from 1998 to 2000. During her tenure as an investment banker, Ms. Jarrett covered biotechnology and pharmaceutical companies, primarily in the San Francisco Bay Area. She currently serves on the board of directors of Arena Pharmaceuticals, Inc. and Syndax Pharmaceuticals, Inc., and previously served on the board of Audentes Therapeutics until its acquisition by Astellas Pharma Inc. in January 2020. Ms. Jarrett holds a B.A. in Economics, cum laude, from Dartmouth College and an M.B.A. from Stanford Graduate School of Business.

What is Jennifer Jarrett's net worth?

The estimated net worth of Jennifer Jarrett is at least $2.21 million as of March 16th, 2021. Ms. Jarrett owns 116,973 shares of Arcus Biosciences stock worth more than $2,213,129 as of May 22nd. This net worth approximation does not reflect any other assets that Ms. Jarrett may own. Additionally, Ms. Jarrett receives a salary of $828,200.00 as COO at Arcus Biosciences. Learn More about Jennifer Jarrett's net worth.

How old is Jennifer Jarrett?

Ms. Jarrett is currently 51 years old. There are 6 older executives and no younger executives at Arcus Biosciences. The oldest executive at Arcus Biosciences is Dr. Juan Carlos Jaen Ph.D., Co-Founder, Pres & Director, who is 64 years old. Learn More on Jennifer Jarrett's age.

What is Jennifer Jarrett's salary?

As the COO of Arcus Biosciences, Inc., Ms. Jarrett earned a total compensation package of $10,896,760.00 in 2020. Ms. Jarrett earned a salary of $125,000.00, stock awards of $90,150.00, non-equity compensation of $75,000.00, and other compensation of $28,171.00.There are 2 executives that earn more than Ms. Jarrett. The highest earning executive at Arcus Biosciences is Dr. Terry J. Rosen Ph.D., Co-Founder, Chairman & CEO, who commands a salary of $932,120.00 per year. Learn More on Jennifer Jarrett's salary.

How do I contact Jennifer Jarrett?

The corporate mailing address for Ms. Jarrett and other Arcus Biosciences executives is 3928 Point Eden Way, Hayward CA, 94545. Arcus Biosciences can also be reached via phone at (510) 694-6200 and via email at [email protected] Learn More on Jennifer Jarrett's contact information.

Has Jennifer Jarrett been buying or selling shares of Arcus Biosciences?

Jennifer Jarrett has not been actively trading shares of Arcus Biosciences over the course of the past ninety days. Most recently, 0 shares of the stock in a transaction that occurred on Sunday, May 22nd. Learn More on Jennifer Jarrett's trading history.

Who are Arcus Biosciences' active insiders?

Arcus Biosciences' insider roster includes Robert Goeltz II (CFO), Juan Jaen (President), Jennifer Jarrett (COO), Terry Rosen (CEO), and Carolyn Tang (General Counsel). Learn More on Arcus Biosciences' active insiders.

Are insiders buying or selling shares of Arcus Biosciences?

During the last twelve months, insiders at the sold shares 13 times. They sold a total of 107,875 shares worth more than $3,765,730.44. The most recent insider tranaction occured on March, 16th when COO Jennifer Jarrett sold 9,617 shares worth more than $304,089.54. Insiders at Arcus Biosciences own 19.7 % of the company. Learn More about insider trades at Arcus Biosciences.

Information on this page was last updated on 3/16/2022.

Jennifer Jarrett Insider Trading History at Arcus Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2022Sell9,617$31.62$304,089.54View SEC Filing Icon  
12/20/2021Sell34,822$41.48$1,444,416.56View SEC Filing Icon  
12/16/2021Sell5,560$39.82$221,399.20View SEC Filing Icon  
9/20/2021Sell30,634$35.18$1,077,704.12View SEC Filing Icon  
6/4/2021Sell1,044$24.91$26,006.04View SEC Filing Icon  
3/16/2021Sell8,661$35.03$303,394.83116,973View SEC Filing Icon  
See Full Table

Jennifer Jarrett Buying and Selling Activity at Arcus Biosciences

This chart shows Jennifer Jarrett's buying and selling at Arcus Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arcus Biosciences Company Overview

Arcus Biosciences logo
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Read More

Today's Range

Now: $18.92
Low: $17.83
High: $19.22

50 Day Range

MA: $28.85
Low: $17.23
High: $37.73

2 Week Range

Now: $18.92
Low: $16.74
High: $49.10

Volume

1,041,387 shs

Average Volume

1,589,070 shs

Market Capitalization

$1.36 billion

P/E Ratio

34.40

Dividend Yield

N/A

Beta

1
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.